Asthma/Steroid Withdrawal Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00395239|
Recruitment Status : Terminated (This project will resume upon the completion of other research committments.)
First Posted : November 2, 2006
Last Update Posted : May 26, 2016
The investigators propose to study the patterns of metabolite changes in subjects with asthma to determine if there is a predictable pattern prior to, and post, clinical exacerbation.
Hypothesis: 1. Metabolite profiles will change prior to detection of a clinical exacerbation in subjects with asthma.
2. There will be a measurable temporal delay before metabolite profiles return to baseline following anti-inflammatory therapy of an exacerbation of asthma.
|Condition or disease||Intervention/treatment||Phase|
|Asthma||Drug: inhaled corticosteroid||Phase 4|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||6 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Temporal Sequence of Inflammatory Mediators During a Controlled Exacerbation of Asthma by Steroid Withdrawal.|
|Study Start Date :||October 2006|
|Primary Completion Date :||October 2015|
|Study Completion Date :||October 2015|
Drug: inhaled corticosteroid
Fluticasone; Budesonide; Ciclesonide Dosage and frequency is patient dependant.
Other Name: Flovent; Pulmicort; Alvesco.
- Metabolite changes in induced sputum [ Time Frame: 20 weeks ]
- Metabolite changes in urine [ Time Frame: 20 weeks ]
- Health related quality of life status [ Time Frame: 20 weeks ]
- Peak expiratory flow measurements [ Time Frame: 20 weeks ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00395239
|University of Alberta Hospital|
|Edmonton, Alberta, Canada, T6G 2B7|
|Principal Investigator:||Irvin Mayers, MD, FRCPC||University of Alberta|